Table 4 Treatment during care at center by presenting status and final biochemical control status
Final Biochemical Control | Presenting Uncontrolled Without Prior Treatment for Acromegaly n = 40 (54.1%) | Presenting Uncontrolled With Prior Treatment for Acromegaly n = 34 (45.9%) | All N = 74 | ||
|---|---|---|---|---|---|
Controlled n = 33 (82.5%) | Uncontrolled n = 7 (17.5%) | Controlled n = 17 (50.0%) | Uncontrolled n = 17 (50.0%) | ||
Treatment Patterns | |||||
 Surgery and medication | 17 | 4 | 2 | 4 | 27 |
(51.5) | (57.1) | (11.8) | (23.5) | (36.5) | |
 Medication only | 2 | 2 | 10 | 12 | 26 |
(6.1) | (28.6) | (58.8) | (70.6) | (35.1) | |
 Surgery only | 14 | 1 | 3 | 1 | 19 |
(42.4) | (14.3) | (17.6) | (5.9) | (25.7) | |
 No treatment | 0 | 0 | 2 | 0 | 2 |
(0.0) | (0.0) | (11.8) | (0) | (2.7) | |
Pituitary surgery | 31 | 5 | 5 | 5 | 46 |
(93.9) | (71.4) | (29.4) | (29.4) | (62.2) | |
Pharmacologic treatment | 19 | 6 | 12 | 16 | 53 |
(57.6) | (85.7) | (70.6) | (94.1) | (71.6) | |
 Somatostatin analogues | 15 | 4 | 9 | 15 | 43 |
(45.5) | (57.1) | (52.9) | (88.2) | (58.1) | |
 Pasireotide | 0 | 0 | 1 | 0 | 1 |
(0.0) | (0.0) | (5.9) | (0.0) | (1.4) | |
 Dopamine agonists | 8 | 2 | 6 | 10 | 26 |
(24.2) | (28.6) | (35.3) | (58.8) | (35.1) | |
 Pegvisomant | 5 | 1 | 2 | 4 | 12 |
(15.2) | (14.3) | (11.8) | (23.5) | (16.2) | |